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This study compares the in vitro activities of enrofloxacin and its main metabolite ciprofloxacin 
against clinical Escherichia coli and non-lactose fermenting enterobacteria isolates from 
chickens. Ten (10) Escherichia coli and 8 non lactose fermenting enterobacteriaceae species 
isolated from a pool of clinical cases at the Microbiology Laboratory of the Veterinary Teaching 
Hospital, University of Agriculture Makurdi were used in this study. Ten-fold serial dilution of 
10 varying concentrations (0.1-50μg/mL) of enrofloxacin and ciprofloxacin were tested against 
the isolates in vitro by Bauer’s disc-diffusion method to determine and compare their 
antimicrobial activities against the isolates. The 18 isolates tested were susceptible to both 
enrofloxacin and ciprofloxacin, and their mean values in the susceptibility of Escherichia coli 
and non-lactose fermenters were significantly different (p < 0.01). The study concluded that the 
clinical isolates are susceptible to both enrofloxacin and ciprofloxacin though ciprofloxacin 
exhibit higher activity. Comparatively, ciprofloxacin was found to be more potent than 
enrofloxacin and the difference statistically significant. Ciprofloxacin was recommended as a 
better choice in the treatment of bacterial infections of chicken in this area compared to 
enrofloxacin. It was also recommended that proper steps should be taken in the administration of 
antimicrobials so as to reduce the incidences of bacterial resistance. 
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INTRODUCTION 
Fluoroquinolones are among the most 
commonly used antibacterial drugs in 
general veterinary practice (Escher et al., 
2011; Kireewan and Suanpairintr, 2017). 
Enrofloxacin and ciprofloxacin are synthetic 
fluoroquinolones which acts by inhibiting 
the DNA gyrase enzyme and commonly 
indicated in intensive poultry farming for the 
treatment of chronic respiratory and 
gastrointestinal infections (Jelena et al., 
2006; Devreese et al., 2014; Vanni et al., 
2014 Ruennarong et al., 2016). They also 
exhibit rapid bactericidal action against a 
wide variety of clinically important 
microorganisms of human and animal origin 
(Jelena et al., 2006; Wayne et al., 2011). 
Though their usage in poultry have been 




restricted in some countries to avoid the 
development of antimicrobial-resistant 
bacteria, they are still of importance in the 
treatment of human infections (Ferrari et al., 
2015). However, ciprofloxacin usage 
particularly has persisted with arguments for 
its use in animals intensified on the basis of 
results of bacterial culture and antimicrobial 
sensitivity testing demonstrating resistance 
to enrofloxacin but susceptibility to 
ciprofloxacin (Sumano and Sunamo, 2001; 
Boothe et al., 2006). 
Ciprofloxacin is a major metabolite of 
enrofloxacin used in human medicine 
(EMEA, 1998), but is only metabolised to a 
limited range of 5–10 % in broiler chickens 
(Redman, 2007; Slana et al., 2014). It also 
has similar spectrum of activity with 
enrofloxacin but with no reported effect 
against gram-positive bacteria (Slana et al., 
2014).  
Ciprofloxacin and enrofloxacin are widely 
used in Nigeria in the management and 
treatment of poultry diseases. Several 
reports point to the fact that the (mis)use of 
fluoroquinolone in chickens have resulted in 
higher incidences of bacteria resistance 
(Abu-Basha et al., 2012; Devreese et al., 
2014; Vanni et al., 2014). According to the 
European Food Safety Authority (EFSA), 
(2014), Salmonella spp., Campylobacter 
jejuni, Campylobacter coli and E. coli 
derived from domestic chickens’ resistance 
to ciprofloxacin stood at 37.3 %, 44.1 %, 
78.4 % and 57.6 %, respectively.  
Resistant bacteria from food animals can 
spread to humans directly or indirectly 
(Adenipekun et al., 2015; Rugumisa et al., 
2016). This microbial resistance as well as 
the spread to human population are growing 
and the outlook for the use of antimicrobial 
drug in the near future is uncertain. This is a 
significant public health concern when 
animal husbandry practices promote 
resistance to medically important antibiotics 
(Anderson et al., 2003; Rugumisa et al., 
2016). Several reports of outbreaks of 
bacterial diseases of poultry are of public 
health concern and have posed enormous 
problem to the poultry industry. The 
indiscriminate use of antimicrobials without 
recourse to susceptibility testing is often 
attributed to be the major cause (Ramanan et 
al., 2013).  
The aims of this study therefore was to asses 
and compare the antimicrobial activities of 
ciprofloxacin and enrofloxacin against 
clinical isolates to ascertaining the most 
appropriate and desirable amongst the two 
thereby limiting the development of resistant 
strains. 
 
MATERIAL AND METHODS 
Escherichia coli and non-lactose 
fermenting enterobacteria isolates 
Ten Avian Escherichia coli and 8 non 
lactose fermenting enterobacteriaceae 
species isolates were tested. The isolates 
were collected from a pool of clinical cases 
from Veterinary Microbiology Laboratory of 
the Veterinary Teaching Hospital, 
University of Agriculture, Makurdi. Proper 
history of each flock including management 
practices and previous treatment were noted. 
Liver, spleen, kidney, lungs and bile 
samples were collected from either 
moribund or dead birds during post-mortem 
examination and labelled individually. 
The isolates were identified on the basis of 
culture, morphological and biochemical 
characteristics. On the basis of microscopic 
examination, morphology of bacteria was 
noted as rod, spiral or filament. It was 
differentiated by Biochemical 
characterization as per Reynolds (2005). On 
cultural basis, MacConkey agar and Eosin-
methylene blue agar (EMBA) were used to 
confirm the identity of the E. coli isolates.  
Swabs collected were directly inoculated 
onto blood agar and MacConkey agar in 
duplicates for every sample inoculum and 
incubated at 37ºC for 24 hours. Similar 
colonies from growth observed were 
“Gram” stained and examined on the basis 
of size, morphology and staining 
characteristics. The Gram negative 
coccobacilli colony types were further 
characterized. 




On MacConkey agar only lactose 
fermenting (LF
+
) pink coloured colonies 
were isolated and sub cultured for further 
characterization to check whether the 
bacteria are E. coli (i.e., there are other 
lactose fermenters like: Klebsiella and 
Enterobacter). The LF
+
 colonies were 
reinoculated on EMB agar for presence of 
metallic sheen characteristics of E. coli, 
while non-lactose fermenting (LF
-
) 
colourless colonies were isolated and sub 
cultured on Muller Hinton agar to obtain 
pure cultures of non-lactose fermenting 
enterobacteriaceae. Pure cultures of both 
isolates grown in nutrient broth were mixed 
with sterile glycerol 1:1 and stored at 
−20°C. 
 
Preparation of antibacterial drug stock 
solutions and dilution trays 
Standard ciprofloxacin and enrofloxacin 
with 99 % purity were both sourced from 
Sigma-Aldriech, USA. The serial dilutions 
of the antimicrobial agents were prepared 
from a stock solution of 10 varying 
concentrations (50 – 0.1 μg/ml) using 
appropriate solvents with positive growth 
control tubes without an antimicrobial agent 
(Andrews, 2001). 
 
Disc diffusion test 
The isolates were tested by the Kirby-
Bauer’s disk-diffusion method as described 
by Bauer et al. (1966). A lawn culture was 
prepared using the primary inoculums by 
spreading the inoculums onto the agar 
surface nicely using a sterile glass spreader 
(sterilized by 70 % alcohol).  
After 15 minutes, ciprofloxacin and 
enrofloxacin (50 – 0.1 μg) impregnated 
discs in triplicates were applied onto the 
agar surface by applicator/ sterile forceps 
with optimum distance between each 
antimicrobial discs. All the varying 
concentrations were prepared on separate 
plates. The petri plates embedded with 
antimicrobial discs were then incubated at 
37ºC for 24 hours. 
Zones of inhibition indicated by a clear area 
around the discs were measured to imply the 
susceptibility to the antimicrobials while 
growth around the disc implies resistance. 
The diameters of the zones of inhibition as 
judged by an unaided eye were measured to 
the nearest whole millimetre (mm) using a 
calibrated scale. The average diameters of 
the zones of inhibition were calculated and 
result interpreted for each antibiotic by 
comparing to the standard chart which 
represents the National Committee for 
Clinical Laboratory Standards (NCCLS) 
subcommittee’s recommendation for the 
particular bacteria of interest. However, as 
the study was not designed to assess the 
incidence of resistance to the antimicrobial 
agents, any isolate that was not sensitive to 
an antimicrobial in the concentration range 
tested was deemed resistant and excluded 
from the analyses. 
 
Data analyses 
The means were determined standard error 
of mean (SEM). Mean difference between 
groups were compared using one-way 
analysis of variance (ANOVA) followed by 
Tukey’s post hoc test, while t-test was 
applied to compare the effect of the two 
fluoroquinolones at varying concentrations 
on all isolates at 5 % significant level (p ≤ 
0.05) using the Statistical Package for Social 
Sciences (SPSS) version 20.0. 
 
RESULTS 
The results from the determination of zones 
of inhibition by disc diffusion test showed 
that Escherichia coli was susceptible to the 
two antimicrobials at concentrations of 
(12.50 - 50.00) μg/mL exhibiting larger 
zones of inhibition in ciprofloxacin than 
enrofloxacin. E. coli showed resistance to 
the two antimicrobials at concentrations 
below 12.50 (μg/mL). The results of 
Escherichia coli isolates susceptibility to 
ciprofloxacin and enrofloxacin as estimated 
from growth inhibition zone diameters are 
presented in TABLE 1. 
The non-lactose fermenters exhibited 
susceptibility to the two antimicrobials 
within concentrations range of 6.25 - 50.50 
(μg/mL) respectively over the entire 24-hour 




incubation period. The non-lactose 
fermenters were however resistant to the two 
antimicrobials in concentrations below 6.25 
(μg/mL). Ciprofloxacin also produced 
higher zones of inhibition TABLE 2. 
The t-test comparing the mean differences in 
zones of inhibition between E. coli and non-
lactose fermenting (NLF) 
Enterobacteriaceae measured at varying 
concentrations of each of the two 
antimicrobial agents at p ≤ 0.05 was 
significantly associated (TABLES 3 and 4). 
 
DISCUSSION 
The majority of the 18 tested isolates in this 
study were susceptible to enrofloxacin and 
ciprofloxacin. In general, the 
fluoroquinolones exhibit excellent activity 
against Enterobacteriaceae, fastidious 
Gram-negative bacteria and some Gram 
positive bacteria (Wayne 
et al., 2011). Many Gram-negative bacteria 
that have become resistant to other classes 
of antibacterial agents remained susceptible 
to the fluoroquinolones (Sárközy, 2001).  
Several reports about in vitro activities of 
the fluoroquinolones against bacterial 
clinical isolates of animal origin exist (Pohl 
et al., 1991; Cid et al., 1994; Šeol, 2005). 
Ciprofloxacin and enrofloxacin have been 
used extensively in this area in recent years 
in the management of poultry diseases 
generally. Šeol, (2005) reported the proved 
usefulness of ciprofloxacin and enrofloxacin  
as potent alternatives for the treatment of
 
TABLE 1: Average zones of inhibition of Escherichia coli against varying concentrations of 
ciprofloxacin and enrofloxacin 
Concentration  Inhibition mean ± SEM (Cipro) Inhibition mean ± SEM (Enro) 
50.000 1.502 ± 0.295 0.367 ± 0.184 
25.000 1.204 ± 0.266 0.178 ± 0.120 
12.500 0.822 ± 0.212 0.014 ± 0.014 
6.250 = = 
3.125 = = 
1.560 = = 
 
TABLE 2: Average zones of inhibition of Non-lactose fermenters against varying 
concentrations of ciprofloxacin and enrofloxacin 
Concentration  Inhibition mean ± SEM (Cipro) Inhibition mean ± SEM (Enro) 
50.000 2.530 ± 0.347 1.279 ± 0.260 
25.000 1.834 ± 0.456 0.896 ± 0.226 
12.500 1.726 ± 0.399 0.546 ± 0.269 
6.250 1.626 ± 0.379 0.413 ± 0.226 
3.125 = = 
1.560 = = 
 
TABLE 3: Comparative effects of ciprofloxacin (C) and enrofloxacin (E) against 
Escherichia coli 
Concentration Difference in mean ± SEM 95 % CI/t-test p-value 
C1 vs E1 1.135 ± 0.357 0.381 to 1.889/ 3.177 0.005 
C2 vs E2 1.026 ± 0.303 0.386 to 1.666/ 3.383 0.003 
C3 vs E3 0.808 ± 0.224 0.334 to 1.281/ 3.601 0.002 
C4 vs E4 = = = 
C5 vs E5 = = = 
C6 vs E6 = = = 





TABLE 4: Comparative effects of ciprofloxacin (C) and enrofloxacin (E) against Non-lactose 
fermenters 
Concentration  Difference in mean ± SEM 95 % CI/t-test p-value 
C1 vs E1  1.251 ± 0.433 0.322 to 2.180/2.889 0.011 
C2 vs E2 0.938 ± 0.509 -0.154 to 2.029/1.843 0.086 
C3 vs E3 1.180 ± 0.481 0.148 to 2.212/ 2.453 0.027 
C4 vs E4 1.214 ± 0.441 0.269 to 2.159/ 2.755 0.015 
C5 vs E5 = = = 
C6 vs E6 = = = 
  
methicillin-resistant strains. This is an 
indication that inappropriate use might 
favour the development of resistant strains 
in vivo. Results of our study are very similar 
to those discussed above and confirmed the 
excellent activity of fluoroquinolones 
particularly enrofloxacin and ciprofloxacin 
against Escherichia coli and 
Enterobacteriaceae. 
In this study, ciprofloxacin has shown to be 
a more potent antimicrobial agent compared 
to enrofloxacin as evidenced in the larger 
zones of inhibition. Abu-Basha et al. (2012) 
and Kotilainen et al. (2005) similarly 
reported of better ciprofloxacin activity 
compared to enrofloxacin against 
Escherichia coli and salmonella infections 
respectively. This is also similar to previous 
reports of Hoogkamp-Korstanje, (1984) and 
Ridgway et al. (1984) whose separate 
studies showed ciprofloxacin of being a 
more potent fluoroquinolone by exhibiting 
the broadest spectrum of activity against all 
Gram-negative bacteria and streptococci 
tested. Prescott and Yielding, (1990) also 
reported of a similar activity of 
ciprofloxacin compared to enrofloxacin 
though both are reported to have structural 
similarity and similar antibacterial spectrum. 
Several other reports of pharmacokinetics of 
ciprofloxacin in domestic animals (Dowling 
et al., 1995; Ovando et al., 2000) showing 
good pharmacokinetic properties and 
therapeutic possibilities exist. The present 
report is expected due to the fact that 
enrofloxacin has been used in this area for 
the treatment of animal infections long after 
the introduction of ciprofloxacin and might 
have developed acquired resistance. 
Cid et al. (1994) reported excellent in vitro 
activities of the fluoroquinolones against E. 
coli. The report indicated that 71.0 % of 
tested strains were sensitive to enrofloxacin, 
26.2% were resistant and 2.7% were 
intermediate in sensitivity, while the 
majority of tested strains (93.4 %) were 
susceptible to ciprofloxacin, 3.8% were 
resistant and 2.7% showed intermediate 
sensitivity. Among the quinolone antibiotics, 
ciprofloxacin was still be the most active or 
potent agent, which also agrees with our 
findings.  
Pohl et al. (1991) have reported that 
relatively high percentages of E. coli isolates 
of bovine origin were resistant to 
enrofloxacin activity in vitro, whereas our 
isolates were highly susceptible to 
enrofloxacin. Hamisi et al. (2014) also 
reported higher resistance (54.5%) among E. 
coli isolates to the fluoroquinolone but with 
a relatively limited resistance to 
ciprofloxacin (3.5%). This difference might 
be explained, in part, by published 
observations that ciprofloxacin is more 
active and potent than other 
fluoroquinolones against most bacteria 
(Lautzenhiser et al., 2001; Rugumisa et al., 
2016).  
Spencer (1996) in an 8-year survey of 29 
425 hospital P. aeruginosa isolates found 
95% susceptibility to ciprofloxacin and 
attributed the higher susceptibility to very 
limited use of ciprofloxacin in veterinary 
practice in Croatia. Contrastingly, Mueller-




Premru and Gubina (2000) found 45.7% of 
the tested strains resistant to ciprofloxacin. 
Shawar et al. (1999), similarly reported a 
higher resistance of 20.7 % to ciprofloxacin. 
In contrast, enrofloxacin showed a relatively 
low activity against P. aeruginosa isolates 
when compared to ciprofloxacin but also 
higher compared to the results of other 
authors (Cid et al., 1994).  
A study by Frazier et al. (2000) showed that 
among marbofloxacin, enrofloxacin, 
ciprofloxacin and difloxacin; marbofloxacin 
has greater Cmax (maximum plasma drug 
concentration curve lg/ml · h) and ACU0-
last (the area under the plasma drug 
concentration versus time curve lg/ml · h) 
compared to enrofloxacin, ciprofloxacin, 
enrofloxacin plus ciprofloxacin combined, 
or difloxacin. Those results suggest that 
even though ciprofloxacin showed better 
activity than enrofloxacin (Ovando et al. 
1999) and similar activity to marbofloxacin, 
because of its pharmacokinetic properties, 
marbofloxacin should be the quinolone of 
choice. 
Grobbel et al. (2007) in their studies showed 
that ciprofloxacin had significantly greater 
in vitro antibacterial activity than 
enrofloxacin against M. haemolytica, P. 
multocida and E. coli, whereas enrofloxacin 
showed greater activity than ciprofloxacin 
against S. aureus. Comparison of the 
sensitivities of individual pathogen isolates 
to enrofloxacin and ciprofloxacin 
highlighted notable differences in the MIC50 
profiles, in particular when considering E. 
coli and S. aureus. Available data showed 
54 of 70 E. coli isolates to be at least one 
log2 step more sensitive to ciprofloxacin 
than enrofloxacin; conversely 33 of 47 S. 
aureus isolates were more sensitive to 
enrofloxacin than ciprofloxacin. This 
difference is reflected in the MIC50 values 
for each agent in the case of E. coli 
(0.016μg/mL for ciprofloxacin and 
0.03μg/mL for enrofloxacin) but not for S. 
aureus (0.12μg/mL for both agents). Higher 
sensitivity of E. coli ATCC 25922 to 
ciprofloxacin and of S. aureus ATCC 29213 
to enrofloxacin was also noted both in 
Grobbel et al. (2007) data and in other 
reports (Riddle et al., 2000). Previous 
studies have shown limited evidence for 
preferential activity for ciprofloxacin against 
E. coli (Zhao et al., 2005) but a more 
consistent body of evidence indicates that S. 
aureus is more susceptible to enrofloxacin 
(Watts et al., 1997; Jones et al., 1998).  
Minimum Inhibitory Concentrations (MICs) 
results also indicates susceptibility to 
ciprofloxacin at 1 (μg/mL) and 2 (μg/mL) 
for enrofloxacin (Pohl et al., 1991; Cid et 
al., 1994) thereby supporting better 
antimicrobial activity of ciprofloxacin when 
compared to enrofloxacin.  
The interest of the medical community in 
fluoroquinolones has not decreased during 
the last 10 years and many new ones have 
been developed and are under investigation 
(Ovando et al., 2004). Ciprofloxacin use in 
human medicine has proved effective in 
several infections (Grobbel et al., 2007). 
Because of its broad and intense activity 
against Gram negative bacteria and the fact 
that no cross-resistance with beta-lactams or 
aminoglycosides occurs, it was also 
suggested to be of considerable usefulness in 
veterinary medicine (Nouws et al., 1988; 
Brown, 1996). 
Our in vitro data show ciprofloxacin to have 
greatest potency against E. coli and non-
lactose fermenting enterobacteria isolates 
tested in comparison to enrofloxacin. In this 
case, our in vitro fluoroquinolone activity 
data suggest that treatment with 
ciprofloxacin is preferential to use of 
enrofloxacin, as ciprofloxacin has the 




The study concluded that enrofloxacin and 
ciprofloxacin are still effective in the 
management and treatment of bacterial 
infections of chicken in Benue State. 
However, ciprofloxacin was reported to 
have exhibited higher activity compared to 
enrofloxacin. The mean values in the zones 




of inhibition against Escherichia coli and 
non-lactose fermenters were significantly 
different (p < 0.01). 
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